The role of full-length apoE in clearance of Gram-negative bacteria and their endotoxins.
CD
aggregation
antimicrobial peptides
bacteria
host defense
infection
innate immunity
lipid A
lipopolysaccharide
Journal
Journal of lipid research
ISSN: 1539-7262
Titre abrégé: J Lipid Res
Pays: United States
ID NLM: 0376606
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
12
2020
revised:
20
04
2021
accepted:
08
05
2021
pubmed:
22
5
2021
medline:
11
3
2022
entrez:
21
5
2021
Statut:
ppublish
Résumé
ApoE is a well-known lipid-binding protein that plays a main role in the metabolism and transport of lipids. More recently, apoE-derived peptides have been shown to exert antimicrobial effects. Here, we investigated the antibacterial activity of apoE using in vitro assays, advanced imaging techniques, and in vivo mouse models. The formation of macromolecular complexes of apoE and endotoxins from Gram-negative bacteria was explored using gel shift assays, transmission electron microscopy, and CD spectroscopy followed by calculation of the α-helical content. The binding affinity of apoE to endotoxins was also confirmed by fluorescent spectroscopy detecting the quenching and shifting of tryptophan intrinsic fluorescence. We showed that apoE exhibits antibacterial activity particularly against Gram-negative bacteria such as Pseudomonas aeruginosa and Escherichia coli. ApoE protein folding was affected by binding of bacterial endotoxin components such as lipopolysaccharide (LPS) and lipid A, yielding similar increases in the apoE α-helical content. Moreover, high-molecular-weight complexes of apoE were formed in the presence of LPS, but not to the same extent as with lipid A. Together, our results demonstrate the ability of apoE to kill Gram-negative bacteria, interact with their endotoxins, which leads to the structural changes in apoE and the formation of aggregate-like complexes.
Identifiants
pubmed: 34019903
pii: S0022-2275(21)00068-7
doi: 10.1016/j.jlr.2021.100086
pmc: PMC8225977
pii:
doi:
Substances chimiques
Endotoxins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100086Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest A. S. is a founder of in2cure AB, a company that is developing therapies based on thrombin-derived host defense peptides. The peptide GKY25 and variants are patent-protected. All other authors declare that they have no conflicts of interest with the contents of this article.